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Abstract  
It is the nature of the calcium signal, as determined by the coordinated activity of a suite of 
calcium channels, pumps, exchangers and binding proteins that ultimately guides a cells fate. 
Deregulation of the calcium signal is often deleterious and has been linked to each of the 
„cancer hallmarks‟. Despite this, we do not yet have a full understanding of the remodeling of 
the calcium signal associated with cancer. Such an understanding could aid in guiding the 
development of therapies specifically targeting altered calcium signaling in cancer cells 
during tumorigenic progression. Findings from some of the studies that have assessed the 
remodeling of the calcium signal associated with tumorigenesis and/or processes important in 
invasion and metastasis are presented in this review. The potential of new methodologies are 
also discussed. 
 
Keywords 
Calcium signaling; calcium remodeling; cancer; calcium channels; calcium pumps; cytosolic 
free Ca
2+ 
 
 
1. Introduction 
Tightly controlled regulation of the calcium signal is essential for appropriate cellular 
functioning, as evidenced by the role of changes in cytosolic free Ca
2+
 in processes such as 
cell proliferation, gene transcription and cell death [1-5]. Typically cells at rest maintain an 
intracellular calcium concentration ([Ca
2+
]i) of approximately 100 nM, while extracellular 
calcium concentrations are much higher, generally within the range of 1-2 mM [3-5]. 
                                                 

Abbreviations: ATP, adenosine triphosphate; EGF, epidermal growth factor; EMT, epithelial-mesenchymal 
transition; IP3R2, inositol 1,4,5-triphosphate receptor, type 2; PMCA, plasma membrane Ca
2+
 ATPase; SERCA, 
sarco/endoplasmic reticulum Ca
2+
 ATPase; SOCE, store operated Ca
2+
 entry; STIM1, stromal interaction 
molecule 1; TRP, transient receptor potential 
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Specialized calcium pumps, channels and calcium binding proteins are used by cells to both 
maintain cellular homeostasis and carry out specific cellular functions, and have been 
referred to as the “molecular toolkit” for calcium signaling [1, 2] (Fig. 1). Changes in 
cytosolic free Ca
2+
 can involve global increases that may be transient or sustained, or highly 
localized such as calcium sparks and puffs, or they may occur as waves or oscillations [1, 5]. 
These changes can be “decoded” by the cell, which allows the ubiquitous calcium signal to 
specifically regulate cellular processes [1, 2]. This complexity in calcium signaling means 
that the deregulation of the calcium signal can be a feature of certain pathological states, 
including cancer [5-7]. Much of the research assessing calcium signaling in cancer has 
focused on determining changes in the expression levels of proteins responsible for 
regulating cytoplasmic free Ca
2+
 concentrations. Following the identification of aberrantly 
expressed calcium channels, pumps or exchangers, researchers often then rely on gene 
silencing approaches and/or chemical inhibitors/activators to evaluate their role in calcium 
signaling and cancer relevant processes (e.g. proliferation and migration). However, in the 
context of cancer, compared to some other disease states, there is a paucity of information 
regarding changes in the nature of the calcium signal that occurs in cancer cells compared to 
non-cancer derived cells. Elucidating such information would improve our understanding of 
the mechanisms underlying cancer progression, and may further help guide researchers to 
identify molecular targets not associated with changes in expression. This review will discuss 
the available evidence for the remodeling of the calcium signal in cancer, and briefly describe 
studies in other disease states to highlight potential approaches that could further improve our 
understanding of alterations in calcium signaling in cancer cells.  
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Fig. 1. Diagrammatic representation of major Ca
2+
 influx/efflux/release and resequestration pathways involved 
in the regulation of [Ca
2+
]i homeostasis in mammalian cells and their associated proteins. Major Ca
2+
 influx 
pathways include those mediated by the transient receptor potential (TRP) family of Ca
2+
 permeable ion 
channels, voltage-gated Ca
2+
 channels (e.g. L-type), purinergic receptors (e.g. P2X), and the SOCE pathway 
components Orai1 and STIM1. Activation of plasma membrane localized G protein-coupled receptors (GPCRs) 
leads to generation of inositol triphosphate (IP3) and subsequent stimulation of IP3 receptors (IP3Rs) located on 
the endoplasmic reticulum (ER), resulting in Ca
2+
 store release. ER localized ryanodine receptors (RYR) and 
mitochondrial Na
+
/Ca
2+
 exchanger (NCLX) also regulate Ca
2+
 in organelles. The sarco/endoplasmic reticulum 
Ca
2+
 ATPase (SERCA), secretory pathway Ca
2+
 ATPase (SPCA), and mitochondrial uniporter (MCU) all 
sequester cytosolic Ca
2+
 into intracellular organelles, while plasma membrane Ca
2+
-ATPases (PMCA) actively 
extrude Ca
2+
 from the cytosol into the extracellular space, and together with the Na
+
/Ca
2+
 exchanger (NCX) play 
a role in restoring resting [Ca
2+
]i. Ca
2+
 signaling also regulates various Ca
2+
 dependent transcription factors (e.g. 
NFAT) and Ca
2+
 binding proteins (e.g. calmodulin). Adapted from references [8-10]. 
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2. Remodeling of the calcium signal in disease  
The development of Ca
2+
 sensitive indicators, such as the fluorescent dyes Fura-2 and Fluo-4, 
and genetically encoded Ca
2+
 indicators have been integral to our understanding and 
interpretation of intracellular calcium signaling by enabling quantitative analysis of Ca
2+
 in 
the cytoplasm and in subcellular organelles [11-16]. These tools have allowed a better 
understanding of how the nature of the calcium signal is remodeled in some diseases. A 
relatively well studied example of pathological remodeling of the calcium signal, reviewed in 
detail elsewhere [17-20], is that which occurs in smooth muscle cells as a consequence of 
vascular disease and injury, including pulmonary hypertension [21, 22], atherosclerosis [23, 
24] and arterial restenosis following angioplasty [25, 26].  
 
Calcium signaling in smooth muscle cells regulates numerous cellular processes including 
proliferation, contraction and gene transcription [27-30]. During vascular injury (through 
mechanical stress and/or growth factors/cytokine exposure), vascular smooth muscle cells 
can undergo phenotypic switching from cells that are largely quiescent and contractile, to 
those exhibiting a more synthetic and proliferative phenotype [18, 31, 32]. This phenotypic 
switching [31], is associated with corresponding changes in the nature of the calcium signal, 
for example a transition from voltage-gated Ca
2+
 entry pathways typical of contractile cells to 
one resembling store-operated and receptor-operated Ca
2+
 entry (SOCE) in proliferating cells 
[20, 33-35]. Kumar et al. demonstrated an example of such remodeling using an in vivo 
model of neointimal hyperplasia [25]. In this model, freshly isolated periadventitial cuff 
injured mouse carotid artery displayed increased [Ca
2+
]i in response to reintroduction of Ca
2+
 
following store depletion using the sarco/endoplasmic reticulum ATPase (SERCA) inhibitor 
thapsigargin, while K
+
 induced depolarization failed to significantly increase [Ca
2+
]i relative 
to uninjured arterial tissue [25]. These findings indicated a switch from a predominately 
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voltage-gated calcium entry pathway to one resembling SOCE following vascular injury. 
This change has been replicated in numerous in vitro models of vascular smooth muscle cell 
remodeling [33-37]. Changes in calcium signaling associated with neointimal hyperplasia are 
associated with increased expression of the transient receptor potential family member 
TRPC1, [25] a protein implicated in the SOCE pathway in some cells [38, 39]. Subsequent 
papers, relevant to this model, also identified roles for Orai1 and stromal interaction molecule 
1 (STIM1) [33, 35, 40, 41], the canonical proteins involved in SOCE [38, 42-46]. These 
included the ability of Orai1 or STIM1 silencing to reduce neointima formation following 
balloon-injury of rat carotid artery [40, 47, 48]. 
 
Vascular smooth muscle injury clearly represents an example of dynamic remodeling of 
calcium signaling in disease and how characterization of these calcium signaling changes can 
lead to a better understanding of disease mechanisms and/or help identify potential 
therapeutic targets. In addition to pathologies involving vascular smooth muscle cell 
remodeling, deregulated calcium homeostasis has also been linked to remodeling of airway 
smooth muscle cells in asthma [49-51], and various other conditions, including those of the 
brain [52] such as Alzheimer‟s disease [53-56]. These studies have included the use of 
advanced assessment of calcium signaling, such as in vivo multiphoton fluorescence lifetime 
imaging microscopy of Ca
2+
 levels in astrocytes in a mouse model of Alzheimer‟s disease 
versus wild type/non-transgenic control animals [56]. 
 
Numerous studies have demonstrated altered expression of various components of the 
“calcium signaling toolkit” [1, 2] in cancer cell lines and in clinical samples (reviewed in 
[10, 57-61]). However, there have arguably been less studies comparing how the nature of the 
calcium signal is altered in cancer and/or changes with tumor progression, especially when 
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compared to other disease states (such as those described above). Although expression 
studies have identified specific Ca
2+
 channels and pumps as drug targets for various cancer 
types including ovarian [62], brain [63, 64], prostate [65, 66], breast [67, 68], and esophageal 
[69], calcium signaling could be altered in cancer progression through other changes, such as 
altered calcium channel or pump localization or activity via disrupted post-translational 
modification. Such changes would be better identified through assessment of the calcium 
signal rather than protein or mRNA levels. Indeed Ingueneau et al. reported that oxidized 
low-density-lipoprotein induced Ca
2+
 influx, and consequent apoptosis in vascular smooth 
muscle cells requires translocation of TRPC1 from an intracellular compartment to 
caveolae/caveolin-1 containing regions of the plasma membrane [70]. The cellular 
localization and activity of other TRP family members is also altered in response to various 
activation pathways in other cell types [71]. Post-translational protein modifications may also 
mask alterations in cellular calcium signaling if interpreted in the absence of functional 
studies. For example, Sundivakkam et al. showed that phosphorylation of STIM1 inhibits 
SOCE in endothelial cells, and is potentially involved in regulating blood vessel permeability 
responses [72]. Some studies have compared calcium signaling in cancer derived and relevant 
non-cancer derived cells and/or other models such as those involving cancer cell 
differentiation. This review will provide a summary of such studies and their significance. 
We will also describe some of the experimental constraints and challenges in characterizing 
calcium signaling changes associated with cancer progression, before discussing some of the 
experimental approaches that may allow these challenges to be addressed.  
 
2.1 Remodeling of the calcium signal in tumor derived cells versus normal cells 
The nature of the calcium signal plays an important role in regulating cellular functions [1, 3] 
including those defined as the “hallmarks of cancer” [59, 73]. One way to identify and 
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understand the possible remodeling of calcium homeostasis in some cancers is to compare the 
nature of the calcium signal in cells or cell lines derived from cancers with those derived 
from non-cancer tissue. Table 1 provides a summary of studies that have assessed differences 
in calcium homeostasis in tumor derived versus non-tumor derived cells. As discussed below, 
many of the changes between tumor and non-tumor derived cells are reflected in very 
specific changes in aspects of the calcium signal, such as the nature of Ca
2+
 influx or the rate 
of recovery of [Ca
2+
]i after stimulation. Some of these changes are illustrated in Fig. 2.   
 
Table 1  
Examples of differences in Ca
2+
 homeostasis from studies comparing tumor versus non-
tumor models. 
Model studied
b
 
Observed change in Ca
2+
 
signaling in tumor model(s) 
relative to control(s)
c
 
Potential consequence(s) of 
altered Ca
2+
 signaling  
References 
Human J82, RT24, T24 and 
5637 bladder urothelial 
carcinoma cell lines vs. 
normal bladder urothelial 
cells from healthy human 
subjects  
Absence of carbachol 
stimulated [Ca
2+
]i increases 
Possible alterations in cell 
adhesion 
[74] 
Human 5367 bladder 
urothelial carcinoma cell line 
vs. normal human urothelial 
primary cell lines from 
healthy controls  
 Mechanically stimulated 
Ca
2+
 wave propagation  
Altered intercellular 
communication via gap 
junctions 
[75] 
Human breast lobular 
infiltrating carcinoma derived 
endothelial cells vs. adult 
human dermal microvascular 
endothelial cells 
 4αPDD (a selective TRPV4 
agonist) and arachidonic acid 
mediated [Ca
2+
]i  influx 
 
 
Role in tumor angiogenesis 
and tumor derived endothelial 
cell migration 
[76, 77] 
Human SKBR3 breast cancer 
cell line vs. non-tumorigenic 
HBL100 mammary epithelial 
cell line 
Remodeled SOCE and store 
depletion kinetics 
Different contribution of 
calcium influx pathways and 
hence altered cellular 
responses to stimuli 
[78] 
Murine RAW 264.7 
monocytic cell line treated 
with human MDA-MB-231 
metastatic breast cancer cell 
line conditioned media vs. 
non-tumorigenic MCF-10A 
breast cell line conditioned 
media 
Induction of sustained [Ca
2+
]i  
oscillations following 
treatment of RAW 264.7 cells 
with MDA-MB-231 
conditioned media 
Potential role in osteoclast 
formation and bone 
metastases  
 
[79] 
Rat colonocytes from DMH 
procarcinogen treated animals 
 Basal [Ca2+]i in colonocytes 
from DMH treated rats 
Reduced apoptosis  [80] 
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vs. colonocytes from vehicle 
treated animals 
Human KYSE-150 
esophageal squamous cell 
carcinoma cell line vs. non-
malignant HET-1A 
esophageal epithelial cell line 

Ca
2+
i oscillations 
May promote cell 
proliferation, migration and 
invasion 
[81] 
Human U251 glioblastoma 
cell line, GBM1 and GBM8 
primary glioblastoma 
multiforme cell lines vs. non-
malignant human primary 
astrocytes 
 SOCE  Promotion of cell invasion [63] 
Human SK-Mel-2, SK-Mel-
24, C8161 and UACC257 
metastatic melanoma cell 
lines vs. control HEMA-LP 
melanocyte cell line 
 SOCE Promotion of cell 
proliferation and migration 
[82] 
Rat pancreatic acinar 
carcinoma cells vs. normal 
acinar cells 
 [Ca2+]i recovery 
following stimulation by 
carbamylcholine and 
peptidergic agonist 
cholecystokinin octapeptide 
Altered cellular responses to 
some stimuli and possible 
reduced apoptosis sensitivity 
via enhanced Ca
2+
 efflux 
[83] 
Human endothelial progenitor 
cells from renal cellular 
carcinoma patients vs. control 
endothelial progenitor cells 
 SOCE  Enhanced proliferation and 
tubulogenesis 
[84] 
Human peripheral blood 
lymphocytes CLL patients vs. 
normal peripheral blood 
lymphocytes from healthy 
controls 
 ATP stimulated [Ca2+]i in 
some CLL patient samples. 
Altered response to ATP 
effect 
[85] 
Human peripheral blood 
leukocytes from CML 
patients vs. normal peripheral 
blood leukocytes from 
healthy controls 
 IP3, ATP and ionomycin 
stimulated [Ca
2+
]i  
Altered oxidative stress 
response 
[86] 
Human CEM and Jurkat 
malignant T cell lines vs. 
normal human peripheral 
blood T cells 
 2+]i  in response to L-
type Ca
2+
 channel activation 
by BAYK8644 and 
ionomycin stimulation 
Altered sensitivity to 
apoptotic inducing agents 
and/or differential regulation 
of Ca
2+
 sensitive pathways 
[87] 
aAbbreviations: 4αPDD, 4α-Phorbal 12,13-didecanoate; ATP, adenosine triphosphate; CLL, chronic lymphocytic leukemia; CML, chronic 
myeloid leukemia; DMH, 1,2-dimethylhydrazine dihydrochloride; IP3, inositol 1,4,5-trisphosphate; SOCE, Store Operated Calcium Entry; 
TRPV4, transient receptor potential cation channel, subfamily V, member 4. 
bIncludes human and/or animal models of both solid and hematological cancers as well as those using conditioned media treatments. 
cArrows indicate either an increase () or decrease () in the nature of the Ca2+ signal in tumor model(s) relative to the non-tumor 
control(s). 
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Fig. 2. Examples of hypothetical remodeling of the Ca
2+
 signal in tumorigenic versus non-tumorigenic cells. 
Each stylized Ca
2+
 trace depicts a remodeling of various aspects of intracellular Ca
2+
 signaling pathways, 
including (a) Ca
2+
 influx pathways, (b) Ca
2+
 efflux pathways, and (c) intracellular Ca
2+
 oscillatory behavior.  
 
Since the identification of the key molecular components of SOCE, namely STIM1 and 
Orai1, there has been a keen interest in determining the role of this calcium influx pathway in 
pathophysiology [88-91]. Indeed, altered expression of STIM1 and/or Orai1 has been 
reported in various cancer types including breast [67], cervical [92], and esophageal [81]. 
Prior to the identification of the STIM and Orai proteins, Baldi et al. conducted studies 
looking into the nature and remodeling of capacitative Ca
2+
 entry (a term used synonymously 
with SOCE) in the tumorigenic (luminal human epidermal growth factor receptor 2 positive) 
SKBR3 cell line, and HBL100, which they used to represent non-tumorigenic breast 
epithelial cells [78]. While both cell lines demonstrated classic SOCE in response to 
thapsigargin mediated store depletion in the absence of extracellular Ca
2+
, the nature of store 
release and Ca
2+
 re-entry (influx) noticeably differed between the two cell lines. While the 
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peak amplitude and initial rate of calcium influx was similar in both cell lines, Baldi et al. 
reported a more sustained and slower return to baseline [Ca
2+
]i levels following SOCE in 
SKBR3 cells. Also, the amplitude of the initial peak representing store depletion appeared to 
be higher in HLB100 cells. The contribution of SOCE and the potential role of other Ca
2+
 
entry pathways were also assessed using various surrogate divalent cations (Ba
2+
, Mn
2+
 and 
Sr
2+
), which demonstrate different permeabilities, and the lanthanide Gd
3+
, which is known to 
block SOCE at low concentrations. From their studies, Baldi et al. characterized two main 
calcium influx pathways in both cell lines; however, their relative contributions to SOCE 
differed between the tumorigenic SKBR3 and non-tumorigenic HLB100 cell lines. These 
findings raised the question of whether differences in the nature of SOCE between both cell 
lines could be a function of tumorigenic remodeling, or merely due to other differences 
between these cell lines [78]. Interestingly, later studies by McAndrew et al. quantified the 
expression levels of Orai1, STIM1 and STIM2 in a panel of non-malignant and breast cancer 
cell lines [67]. Of the six breast cancer cell lines assessed, SKBR3 cells expressed the lowest 
levels of Orai1 mRNA (relative to the non-tumorigenic cell line 184A1), and an altered 
STIM1/STIM2 ratio compared to other tumorigenic cell lines. Unfortunately, while mRNA 
expression levels of the STIM and Orai family members was comprehensively characterized, 
a comparison of calcium signaling dynamics in all cell lines was not performed. Such a study 
may provide insight into the functional consequences of altered Orai1, STIM1 and STIM2 
expression not only between non-tumorigenic and tumorigenic cell lines, but also between 
breast cancer cell lines representing different molecular subtypes.  
 
Investigation into the contribution of SOCE, this time in glial cells, revealed a remodeling of 
this Ca
2+
 entry pathway in the form of a two-fold increase in the amplitude of SOCE in 
cultured human primary malignant glioblastoma multiforme cells relative to a non-malignant 
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human primary astrocyte control [63]. Further investigation revealed an increase in Orai1 
mRNA levels in only two of the three glioblastoma multiforme cell lines assessed, despite 
SOCE being increased in all three malignant cell lines. This further supports the importance 
of comparing functional calcium signaling in cancer and non-cancer control cells in addition 
to assessment of gene expression. Enhanced SOCE indicated by significantly increased 
[Ca
2+
]i peak amplitude following store depletion, and corresponding to increased Orai1 
protein expression, was also shown in four metastatic melanoma cell lines relative to a 
control melanocyte cell line [82]. Zhu et al. recently identified a remodeling of the SOCE 
pathway in an esophageal squamous cell carcinoma derived cell line KYSE-150, relative to a 
non-tumorigenic esophageal epithelial cell line HET-1A [81]. In addition to assessing SOCE 
specifically, the authors also evaluated differences in global calcium signaling using live cell 
imaging in the absence of a specific stimulus. Esophageal squamous cell carcinoma cells 
displayed a significantly higher degree of spontaneous intracellular Ca
2+
 oscillations 
compared to normal cells, 76% versus 26%, respectively [81]. These oscillations could be 
inhibited by pharmacologically mediated SOCE blockade with SKF96365 and Orai1 
silencing [81]. This is significant because of the importance of the nature of calcium 
oscillations in the regulation of the transcription factors that regulate genes important in cell 
proliferation and/or migration [93-96]. 
 
Altered expression of other Ca
2+
 entry pathways, in particular certain members of the 
transient receptor potential (TRP) family of Ca
2+
 permeable ion channels has also been 
identified in various cancer types including breast [68, 97, 98], prostate [61, 99], ovarian 
[62], esophageal [69], and brain [64] (reviewed in [61, 100]). Studies comparing cancer and 
non-cancer derived cells have also shown changes in calcium signaling mediated by some 
members of the TRP channel family. Early studies by Fiorio Pla et al. investigating 
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mechanisms of endothelial cell migration, a process important in angiogenesis in tumors, 
showed that the second messenger arachidonic acid induced a significantly higher Ca
2+
 
response in breast tumor derived endothelial cells relative to normal dermal endothelial cells 
[76]. This difference appears to be mediated by the TRP channel family member TRPV4, 
since arachidonic acid and the TRPV4 agonist 4αPDD stimulated Ca2+ entry in tumor 
derived endothelial cells is attenuated by TRPV4 silencing [77]. Another TRP family 
member showing altered activity in certain cancer types is the cold stimulus activated 
TRPM8, which mediated significantly greater current density (pA/pF) (determined via whole 
cell patch clamp) in an androgen sensitive primary prostate cancer cell line relative to normal 
primary prostate epithelial cells in response to icilin stimulation [66].  
 
It is now well recognized that tumor cells do not exist in isolation but are rather part of a 
larger microenvironment comprising multiple cell types, including immune, endothelial and 
other supporting stromal cells, which together act to maintain and promote tumor growth and 
progression (reviewed in [101-104]). There is increasing evidence to suggest that the 
recruitment of endothelial progenitor cells from the bone marrow plays an important role in 
tumoral neoangiogenesis (reviewed in [105, 106]), which is essential for sustaining tumor 
growth and facilitating metastatic spread [107]. Remodeling of calcium signaling was 
recently identified in endothelial progenitor cells derived from patients with renal cell 
carcinoma relative to healthy controls [84]. Lodola et al. showed that the amplitude of SOCE 
was significantly higher in endothelial progenitor cells derived from renal cell carcinoma 
patients compared to those derived from healthy controls. This finding was supported by a 
corresponding increase in the transcript and protein levels of STIM1, Orai1 and TRPC1 in 
endothelial progenitor cells derived from renal cell carcinoma patients. Through a series of 
experiments, the authors provided evidence to support the hypothesis that the increase in 
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SOCE in endothelial progenitor cells derived from renal cell carcinoma patients increased 
proliferation and tubulogenesis, processes important in endothelial progenitor cell mediated 
neoangiogenesis [84].  
 
Another example of the importance of calcium signaling in cells of the tumor 
microenvironment was shown by Tiedemann et al. when they demonstrated significantly 
increased intracellular Ca
2+
 oscillatory behavior in osteoclast (bone resorbing) precursor cells 
following stimulation with conditioned media from tumorigenic breast cancer cells, but not 
non-tumorigenic breast epithelial cells [79]. This increase in conditioned media stimulated 
Ca
2+
 oscillations was associated with a significant increase in osteoclast number and size, an 
effect that was effectively inhibited by treatment with the Ca
2+
 chelator BAPTA (1,2-bis(o-
aminophenoxy)ethane-N,N,N‟,N‟-tetraacetic acid). This further supported a role for Ca2+ in 
the process of breast cancer cell induced osteoclastogenesis [79]. This finding is significant 
as increased osteoclast activity mediated by metastatic breast cancer cells in the bone 
microenvironment can lead to bone destruction, increased fracture risk and pain in cancer 
patients [79, 108]. 
 
The studies described above provide evidence for the value of comparing calcium signaling 
in tumor-derived cells with those derived from non-diseased tissue. However, in some cases 
experimental limitations make it difficult to determine how well these changes in calcium 
signaling actually reflect the changes associated with tumor development. In section 4 we 
will describe some of the methodological advancements that may address these limitations. 
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3. Differentiated cell lines as a model to study remodeling of calcium signaling in 
cancer cells 
In order to overcome some of the difficulties associated with matching cancer cells to 
suitable normal control cells, a number of researchers have turned to tumorigenic cell lines in 
which a differentiated phenotype can be induced as a surrogate for „normal‟ or at least less 
tumorigenic cells. The use of specific cell culture methods and/or stimulation with selected 
growth factors/pharmacological agents to induce a different cellular phenotype is not unique 
to cancer cell line models. Researchers investigating methods of culturing primary vascular 
smooth muscle cells observed that under certain culture conditions, smooth muscle cells can 
transition between a differentiated contractile and typically quiescent phenotype to a 
dedifferentiated and synthetic phenotype, characterized by a loss of contractile response, 
altered morphology and increased proliferative and migratory potential [109-114]. The 
phenotypic switching of vascular smooth muscle cells in culture is associated with changes in 
the nature of the calcium signal [33-35]. These changes include an increase in Ca
2+
 influx via 
SOCE. Any in vitro model cannot be expected to fully recapitulate conditions and 
remodeling events that occur in vivo. However, similar calcium signaling remodeling has 
been reported using an in vivo model of vascular injury [25]. Such agreement between in vivo 
and in vitro models of smooth muscle injury suggests that the differentiation or 
dedifferentiation of cell lines may be a useful approach to study the remodeling of calcium 
signaling in other disease states, including cancer. As described below, alterations in calcium 
signaling with differentiation have been reported in a variety of cancer cell lines including 
those of the breast, colon and lung. 
  
In a similar way to groups culturing vascular smooth muscle cells to induce a „switch‟ from a 
contractile to a synthetic phenotype [33, 35, 41], Bidaux et al. developed a model of prostate 
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epithelial cell dedifferentiation to aid in characterizing expression and activity of the TRP 
family member, TRPM8, during prostate cancer progression [66]. The Na
+
 and Ca
2+
 
permeable TRPM8 channel has been identified as a potential diagnostic/prognostic marker in 
prostate cancer [99, 115-118]. Prolonged culture of primary prostate epithelial cells led to a 
less differentiated phenotype corresponding with a loss of androgen receptor expression, 
which was associated with decreased TRPM8 activity in response to stimulation with the 
TRPM8 activator menthol. Confocal imaging of TRPM8 localization demonstrated a loss of 
TRPM8 from the plasma membrane as a consequence of dedifferentiation [66]. Other 
changes in Ca
2+
 influx pathways as a consequence of differentiation are reflected by the 
effects of the differentiating agent 9-cis retinoic acid on N- and S-type neuroblastoma cells 
derived from the SH-SY5Y neuroblastoma cell line [119]. Differentiation of the more 
malignant N-type cells is associated with the down regulation of SOCE, leading the authors 
to propose the utility of therapeutically targeting SOCE as a means for promoting 
neuroblastoma cell differentiation [119]. In the A549 lung cancer cell line, differentiation via 
all-trans-retinoic acid is associated with enhanced Ca
2+
 influx following trypsin-mediated 
Ca
2+
 store depletion [120], demonstrating that the down regulation of Ca
2+
 influx is not a 
ubiquitous feature of the differentiation of cancer cell lines. 
 
Pharmacologically induced differentiation of cancer cells using agents such as those acting 
on histone deacetylase, including short chain fatty acids and their derivatives, and the protein 
kinase C activator phorbal 12-myristate 13-acetate (PMA) is another method used to study 
altered calcium signaling and homeostasis in cancer cells [121-125]. Recently, Varga et al. 
showed that short chain fatty acid and/or PMA induced differentiation of the MCF-7 breast 
cancer cell line correlates with an increase in plasma membrane Ca
2+
 ATPase isoform 4b 
(PMCA4b) protein and mRNA expression [121]. PMCA4 was also detected in normal breast 
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tissue sections following immunohistochemical staining [121]. These findings are in 
agreement with an earlier study, which showed decreased PMCA4 mRNA expression in a 
panel of breast cancer cell lines relative to non-tumorigenic breast epithelial cell lines [126]. 
In order to further investigate the effect of differentiation on the nature of the calcium signal, 
Varga et al. developed an MCF-7 cell line stably expressing the genetically encoded Ca
2+
 
indicator GCaMP2 [121]. Valerate and/or the combination of valerate and PMA induced 
differentiation resulted in a remodeling of the calcium signal characterized by reduced peak 
[Ca
2+
]i following adenosine triphosphate (ATP) mediated store depletion, as well as a much 
faster recovery of [Ca
2+
]i to baseline, relative to undifferentiated control cells. Peak [Ca
2+
]i 
was also greatly reduced in differentiated cells following calcium ionophore treatment. The 
authors proposed a role for PMCA4b in maintaining Ca
2+
 homeostasis in normal mammary 
epithelial cell physiology, a function that may be lost as cells progress to a tumorigenic 
phenotype [121].  
 
Breast cancer cells are not the only cancer cell type demonstrating a differentiation induced 
remodeling of the calcium signal corresponding to altered PMCA expression and function. 
Indeed, Ribiczey et al. showed increased PMCA4b expression following short chain fatty 
acid induced differentiation of a gastric and colon carcinoma cell line, corresponding to a two 
to three fold increase in PMCA transport activity in isolated microsomal membrane vesicles 
[123]. Pharmacologically induced differentiation also resulted in increased PMCA2, PMCA3 
and PMCA4 isoform expression in a human neuroblastoma cell line, which is associated with 
a faster recovery rate of [Ca
2+
]i to baseline after depolarization [127]. 
 
In addition to plasma membrane localized Ca
2+
 efflux pathways, evidence of remodeling of 
intraorganellar Ca
2+
 sequestration pathways and homeostasis, specifically those involving the 
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sarco/endoplasmic reticulum Ca
2+
 ATPases (SERCAs), has also been demonstrated following 
differentiation of cancer cells. SERCAs play an important role in the regulation of 
endoplasmic reticulum Ca
2+
 homeostasis and altered expression of the SERCA isoforms, 
particularly SERCA3, has been identified in various cancer subtypes [124, 128-130]. 
Arbabian et al. demonstrated an increase in SERCA3 protein expression upon short chain 
fatty acid induced differentiation in a panel of lung adenocarcinoma cell lines [122]. Using 
A549 lung carcinoma derived cell lines stably expressing the genetically encoded calcium 
indicator GCaMP2, the authors reported significantly decreased Ca
2+
 store release induced by 
the SERCA inhibitor thapsigargin in phenylbutyrate differentiated cells relative to untreated 
control, whereas subsequent SOCE was essentially unaltered [122]. This finding was partially 
attributed to increased levels of the lower Ca
2+
 affinity SERCA3 isoform relative to that of 
the higher Ca
2+
 affinity SERCA2 isoform in differentiated cells [122]. Increased SERCA3 
expression and altered Ca
2+
 homeostasis was also shown in the gastric carcinoma cell line, 
KATO-III, following butyrate induced differentiation [124]. Differentiation of KATO-III 
cells was associated with increased basal cytosolic Ca
2+
 relative to non-differentiated cells, 
and decreased thapsigargin induced endoplasmic reticulum Ca
2+
 store release [124], as was 
reported by Arbabian et al. in differentiated A549 cells [122].  
 
The findings from the various models of differentiation described above provide further 
evidence of a remodeling of calcium signaling during the process of tumorigenesis. They also 
provide a rationale for future in vitro investigations using matched normal and tumorigenic 
primary and/or immortalized cell lines, as well as carefully designed in vivo experiments, to 
further study remodeling of the calcium signal in the context of cancer.   
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 19  
4. Modulation of the calcium signal during processes associated with invasion and 
metastasis 
The transformation from benign to malignant disease is a leading cause of cancer related 
death [131, 132], and therapies targeted towards inhibiting processes important in the 
invasion-metastasis cascade are a major focus of current cancer research [131-136]. 
Therefore understanding the remodeling of the calcium signal in invasion and metastasis 
could aid in the identification of novel therapeutic targets. Recently, researchers have used 
various models to replicate processes important in invasion and metastasis in order to help 
define changes in calcium signaling that may be important in tumor progression. 
 
In order for cancer cells to successfully metastasize they must first acquire the ability to 
invade and migrate into their surrounding microenvironment and local vasculature before 
disseminating to a distant site [137-140]. A functional role for Ca
2+
 in the directional 
migration of lung fibroblasts was elegantly demonstrated using real time confocal Ca
2+
 
imaging, where highly organized Ca
2+
 signals known as “calcium flickers”, which are tightly 
regulated in both space and time were visualized in response to a chemotactic agent [141]. 
The stretch activated Ca
2+
 permeable TRP family member, TRPM7, together with inositol 
1,4,5-triphosphate receptor, type 2 (IP3R2) stimulated Ca
2+
 release were implicated in 
mediating these calcium flickers. Subsequent studies have shown a role for TRPM7 in the 
migration of both nasopharyngeal [142] and pancreatic carcinoma cell lines [143]. For a 
detailed review of the role of calcium in cancer metastasis refer to [59]. 
 
The SOCE pathway appears to play an important role in migration and invasion in various 
cancer cell types [63, 81, 82, 144-146]. Indeed, evidence of a role for Orai1 and/or STIM1 in 
cell migration and invasion has been shown both in vitro and in vivo [81, 82, 92, 144]. 
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Recently, Umemura et al. showed pharmacological inhibition of SOCE and/or gene silencing 
of either STIM1 or Orai1 significantly decreased melanoma cell line migration in vitro, and 
the formation of lung metastasis in vivo [82]. Some studies have also provided important 
evidence that some cancer cell lines are more sensitive to silencing of SOCE components 
than their appropriate non-malignant cell line controls. Indeed, Motiani et al. showed that the 
silencing of STIM1 and Orai1 significantly reduces serum stimulated invasion of 
glioblastoma cells relative to normal human primary astrocytes [63].  
 
Vascularization of tumoral tissues via induction of angiogenesis represents one of the original 
cancer hallmarks [73] and intracellular calcium signaling plays an important role in 
regulating this process [147-149]. Using live cell imaging Fiorio Pla et al. showed that 
migrating breast tumor endothelial cells, located at the wounded edge of a scratched cell 
monolayer, responded with a significantly higher Ca
2+
 influx with TRPV4 activation 
compared to non-migrating endothelial cells located away from the wound edge [77]. These 
studies suggest that migrating endothelial cells, which are important in tumor angiogenesis, 
undergo a remodeling of their calcium signaling and this is associated with increased 
responsiveness to TRPV4 activators. This remodeling may be due to dynamic changes in 
TRPV4 localization, since arachidonic acid (an effector in the angiogenic growth factor 
signaling pathway) caused redistribution of TRPV4 to the plasma membrane in endothelial 
cells, a function related to remodeling of the actin cytoskeleton. TRPV4 gene silencing 
abolished the migratory response of breast tumor endothelial cells to arachidonic acid [77], 
providing further evidence of a role for TRPV4 mediated Ca
2+
 influx in arachidonic acid 
stimulated breast tumor endothelial cell migration.  
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The ability of polarized cancer epithelial cells to transition to a mesenchymal and migratory 
state via epithelial-mesenchymal transition (EMT), a process thought to play a role in cancer 
metastasis [150-152], has recently been linked to calcium signaling [153]. Davis et al. 
demonstrated that mechanical wounding of an MDA-MB-468 breast cancer epithelial cell 
monolayer, a process shown to induce expression of the EMT marker vimentin in other 
tumorigenic and non-tumorigenic breast epithelial cell lines [154, 155], resulted in the 
propagation of a calcium wave from the site of wounding [153]. In addition, treatment of 
MDA-MB-468 breast cancer cells with exogenous epidermal growth factor (EGF) (another 
inducer of EMT in this model) also resulted in increases in cytosolic free Ca
2+
. Although the 
buffering of intracellular Ca
2+
 inhibited EMT induction by EGF, the nature of the calcium 
signal was critical to the ability of agents to induce EMT, and the Ca
2+
 permeable ion channel 
TRPM7 was identified as a key regulator of EGF-induced EMT in MDA-MB-468 breast 
cancer cells [153]. Further remodeling of the calcium signal was also demonstrated in this 
model of EMT, whereby cells induced to undergo EMT exhibited decreased Ca
2+
 influx 
induced by the purinergic receptor agonist ATP and the protease activated receptor 2 
activator trypsin, as well as reduced SOCE [156]. In addition, cells in the more invasive 
mesenchymal state displayed significantly faster recovery of [Ca
2+
]i after ATP stimulation 
[157]. Hence, EMT at least in this breast cancer cell line model is associated with a 
remodeling of the calcium signal [156]. A different remodeling of Ca
2+
 signaling as a 
consequence of EMT has been reported by Hu et al., who used TGFβ to induce EMT in 
MCF-7 breast cancer cells, where EMT was associated with an increase in SOCE [158]. 
Further studies in these and others models of changes implicated in metastasis are required to 
fully understand how Ca
2+
 signaling may be altered in cells undergoing changes associated 
with the acquisition of a more invasive phenotype. 
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5. Novel methods for studying changes in the nature of the calcium signal in cancer 
Whilst valuable in contributing to our understanding of the remodeling of the nature of the 
calcium signal in tumorigenesis, findings from studies such as those presented above can 
suffer limitations by virtue of the low throughput nature of the methods used. Methods often 
restrict the number of tumorigenic and normal (or non-tumorigenic) cell lines that can be 
compared. This may be particularly important in research using breast cancer cell lines, 
which are commonly classified according to molecular subtype [159-162] and represent an 
example where the use of multiple controls, both tumorigenic and non-tumorigenic, is often 
desirable in order to represent the heterogeneity seen in breast cancer [163-165]. This 
limitation can be partially addressed through use of high throughput devices, such as the 
fluorometric imaging plate reader (FLIPR®, Molecular Devices), which could enable the 
simultaneous analysis of multiple cell lines in microplates of 96, 384 or 1536 wells [166].  
Although such instrumentation has been used to assess Ca
2+
 signals in breast cancer cells [67, 
68, 153, 156, 157], their potential in fully characterizing many tumorigenic and non-
tumorigenic cell lines has not been fully utilized. 
 
Development of the Ca
2+
 sensitive fluorescent dyes (e.g. Fura-2 and Fluo-4) has been integral 
to our current understanding of intracellular calcium signaling in both physiology and 
pathophysiology. However, as discussed in section 2.1, there is an increasing interest in the 
remodeling of the calcium signal as a consequence of the interaction between tumor cells and 
cells of their microenvironment. The assessment of calcium signaling in vivo using advanced 
imaging techniques such as multi-photon microscopy is increasing, and enables investigation 
of calcium signaling in the context of the cellular microenvironment [56, 167-169]. While the 
development of the acetoxymethyl ester forms of the fluorescent dyes (e.g. Fura-2/AM), has 
provided a relatively non-invasive means of measuring intracellular calcium signaling in 
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living cells [170], their ability to become sequestered into Ca
2+
 containing intracellular 
organelles and/or extruded by multidrug transporters, including MDR1 (also known as P-
glycoprotein), [171-173] (up-regulated in many cancer cells [174]) can limit their utility in 
long term studies of calcium signaling in vivo. The range of genetically encoded Ca
2+
 
indicators now available (reviewed in [175-177]), which can be stably transfected into living 
cells, allows the measurement of calcium events over extended periods [176]. In vivo Ca
2+
 
imaging has provided enormous insight into the role of calcium signaling in living systems 
(reviewed in [178]). Whilst this method is predominately currently used to study calcium 
signaling in neuronal networks [179-181], the potential exists for these tools to provide 
insight into the remodeling of the calcium signal during tumorigenic processes such as 
invasion and metastasis in vivo.  
 
5. Conclusion  
While expressional changes in proteins responsible for regulating intracellular calcium 
signaling, such as channels, pumps and exchangers, have been characterized in various 
cancer cell lines and tissues, specific alterations in the nature of the calcium signal as a cause 
and/or consequence of tumorigenesis are less well described. Remodeling of the calcium 
signal is a feature of various disease states, and has been well characterized in models of 
vascular injury and disease. The important role of calcium signaling in proliferation, cell 
death, and invasion and metastasis, represent multiple opportunities for targeting altered 
calcium signaling during the course of tumorigenesis. Models enabling comparison of the 
calcium signal between tumorigenic and non-tumorigenic phenotypes combined with the use 
of high throughput and/or advanced Ca
2+
 imaging methodologies may further aid in the 
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translation of altered calcium signaling assessment into the development of targeted cancer 
therapeutics. 
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Highlights 
 Deregulated Ca2+ signaling is linked to each of the „cancer hallmarks‟. 
 Altered Ca2+ transporter protein expression is associated with some cancers. 
 Specific aspects of the Ca2+ signal appear to be altered in some cancer cells. 
 The nature of altered Ca2+ signaling in cancer is not completely understood.  
 Understanding altered Ca2+ signaling in cancer may guide therapeutic targeting. 
